Menopause Practice Questions

Q: A 50 year old postmenopausal woman comes with complaints of bleeding per vaginum. Which one of the following investigations is NOT required?

Diagnostic laparoscopy. ***Diagnostic laparoscopy*** - **Diagnostic laparoscopy** is NOT indicated in the routine workup of **postmenopausal bleeding** as it does not allow direct visualization of the **endometrial cavity**, which is the primary site of pathology in PMB. - It is an invasive surgical procedure used to visualize pelvic and abdominal organs **externally** and is reserved for evaluating conditions like **endometriosis**, **pelvic inflammatory disease**, **adnexal masses**, or **ectopic pregnancy**. - The key investigations for PMB focus on evaluating the **endometrium** and **cervix**, not the peritoneal cavity or external surface of pelvic organs. *Hysteroscopy* - **Hysteroscopy** involves direct visualization of the **uterine cavity** and is crucial for identifying and biopsying focal lesions like **polyps**, **submucosal fibroids**, or **endometrial cancer** that can cause postmenopausal bleeding. - It allows for targeted biopsy of suspicious areas that might be missed by blind endometrial sampling. *Pap smear* - A **Pap smear** is essential for screening for **cervical cancer** and **precancerous lesions** of the cervix, which can present as postmenopausal bleeding. - Although it primarily screens the cervix, abnormal cytology indicates the need for further investigation with colposcopy and biopsy. *Endometrial biopsy* - **Endometrial biopsy** is the **gold standard** for investigating postmenopausal bleeding, as the most common cause is **endometrial cancer** or **hyperplasia**. - It provides histological samples of the endometrium to rule out malignancy and confirm benign causes like **atrophic endometrium**.

Q: Which of the undermentioned conditions does not cause postmenopausal vaginal bleeding?

Benign cystic teratoma of ovary. ***Benign cystic teratoma of ovary*** - A **benign cystic teratoma** of the ovary is a germ cell tumor that typically does **not cause hormonal changes** leading to vaginal bleeding. - While it can cause symptoms such as **abdominal pain** or a palpable mass, it is not directly associated with postmenopausal vaginal bleeding. *Carcinoma of cervix* - **Cervical cancer** is a well-known cause of both **intermenstrual** and **postmenopausal vaginal bleeding**, especially following intercourse. - The abnormal growth of cells on the cervix can be fragile and bleed easily, leading to the symptom. *Senile vaginitis* - Also known as **atrophic vaginitis**, this condition occurs due to the **thinning and inflammation** of the vaginal walls due to decreased estrogen levels after menopause. - The fragile, dry tissues can easily tear and bleed, leading to postmenopausal bleeding or spotting. *Prolapse of uterus with decubitus ulcer* - A **decubitus ulcer** can form on the prolapsed cervix or vaginal wall due to **chronic friction and irritation**, particularly in cases of severe uterine prolapse. - The raw, ulcerated surface readily **bleeds**, especially with minor trauma or straining, causing postmenopausal vaginal bleeding.

Q: Menopause is associated with the following except:

Delusion. ***Delusion*** - Delusions are a feature of **psychotic disorders** and are not directly associated with the physiological changes of menopause. - While menopause can affect mood and cognitive function, it does not typically cause **psychotic symptoms** like delusions. *Loss of libido* - The decline in **estrogen levels** during menopause can lead to vaginal dryness and discomfort during intercourse, which can contribute to a loss of libido. - Hormonal changes also directly impact sexual desire, making it a common menopausal symptom. *Ischemic heart disease* - Estrogen has a **cardioprotective effect**, and its decline after menopause increases women's risk for **ischemic heart disease**. - The absence of estrogen contributes to changes in lipid profiles and endothelial function, predisposing women to cardiovascular events. *Osteoporosis* - Estrogen plays a crucial role in maintaining **bone density**, and its reduction during menopause accelerates bone loss. - This loss of bone mass significantly increases the risk of **osteoporosis** and fractures in postmenopausal women.

Q: A 58 year old woman, post menopausal for last 8 years comes with history of spotting per vaginum. What is the most likely cause?

Atrophic vaginitis. ***Atrophic vaginitis*** - **Most common cause** of postmenopausal bleeding, accounting for **60-70% of cases**. - Due to **decreased estrogen levels** after menopause, the vaginal epithelium and endometrium become thin, dry, and fragile. - This leads to **easy bleeding** from minimal trauma, presenting as spotting. - In a woman 8 years postmenopausal, atrophic changes are the statistically most likely cause. *Endometrial carcinoma* - **Must always be ruled out** in any woman with postmenopausal bleeding - this is the golden rule. - Accounts for approximately **10% of postmenopausal bleeding cases**. - While statistically less common than atrophy, requires investigation with **endometrial biopsy or transvaginal ultrasound**. - Risk factors include obesity, nulliparity, late menopause, and unopposed estrogen exposure. *Endometrial hyperplasia* - Results from **unopposed estrogen stimulation** causing excessive endometrial growth. - More commonly presents with **heavier or prolonged bleeding** rather than spotting. - Less likely in a woman 8 years postmenopausal without hormone therapy. - Can be a precursor to endometrial carcinoma if left untreated. *Estrogen replacement therapy* - Can cause **breakthrough bleeding or spotting** if used. - The question stem does not mention the patient is on hormone replacement therapy. - If present, would be an important consideration in the differential diagnosis.

Q: Which of the following is an established benefit of Hormone Replacement Therapy (HRT)?

Decreased risk of vertebral fracture. ***Decreased risk of vertebral fracture*** - HRT is **one of the most well-established benefits** for **prevention of osteoporosis and fractures**, including vertebral fractures. - Estrogen plays a crucial role in maintaining **bone mineral density** by inhibiting osteoclast activity and promoting osteoblast function. - Multiple studies, including the **Women's Health Initiative (WHI)**, have demonstrated a **significant reduction in hip, vertebral, and other osteoporotic fractures** in women taking HRT. - This benefit is recognized by **ACOG, NAMS, and international menopause societies** as a primary indication for HRT in appropriate candidates. *Decreased risk of endometrial cancer* - **Unopposed estrogen therapy** actually **increases the risk of endometrial cancer** due to hyperplasia of the endometrium. - To counteract this, **progestin is added** in women with a uterus receiving HRT, which reduces but does not eliminate the risk increase. - Combined HRT does not provide a net decreased risk below baseline. *Decreased risk of breast cancer* - Combined **estrogen-progestin HRT** has been consistently associated with an **increased risk of breast cancer**, especially with longer durations of use (>5 years). - This was clearly demonstrated in the **WHI trial** and remains a major consideration when prescribing HRT. - Estrogen-only HRT might have a neutral or slightly increased risk, but never a decreased risk. *Decreased risk of colon cancer* - While some observational studies and the **WHI trial** initially showed a reduced incidence of colorectal cancer with HRT, this is **not considered an established or primary indication** for HRT. - Subsequent analyses have shown **inconsistent results**, and any benefit is offset by increased risks. - Current guidelines do **not recommend HRT** for colorectal cancer prevention.

Q: Treatment of post menopausal osteoporosis are all EXCEPT

Magnesium and Zinc. ***Magnesium and Zinc*** - While **magnesium** and **zinc** are essential for overall health, their role as primary therapeutic agents for established postmenopausal osteoporosis is **unproven** and is not standard treatment. - They are considered **trace elements** and their deficiency can affect bone health, but supplementation alone is not sufficient to treat osteoporosis. *Estrogen* - **Estrogen replacement therapy** was historically used for postmenopausal osteoporosis due to its role in preventing bone loss, but its use is now limited due to **adverse effects** like increased risk of breast cancer and cardiovascular events [1]. - It is still considered in select cases for symptom relief and bone health, but generally at the lowest effective dose for the shortest duration [1]. *Calcium, Vit D supplementation* - **Calcium and Vitamin D supplementation** are fundamental components of osteoporosis management by supporting bone mineralization and calcium homeostasis [2]. - Adequate intake is critical for both **prevention** and **treatment**, often used in conjunction with other pharmacologic agents [2]. *Raloxifene* - **Raloxifene** is a **selective estrogen receptor modulator (SERM)** that acts as an estrogen agonist on bone, thereby reducing bone resorption and increasing bone mineral density [1]. - It is used in the treatment and prevention of postmenopausal osteoporosis, with the added benefit of reducing the risk of invasive breast cancer [1].

Q: Gonadotrophins remain elevated after menopause for :

Rest of life. **Correct Answer: Rest of life** - Following menopause, the ovaries cease to produce significant amounts of **estrogen** and **progesterone**. - This lack of negative feedback on the **hypothalamic-pituitary axis** leads to persistently elevated levels of **gonadotropins (FSH and LH)** throughout the remainder of a woman's life. - The **ovarian failure** and subsequent lack of estrogen production are irreversible, resulting in permanent elevation of gonadotropins. *Incorrect: 5 years* - While gonadotropin levels are high during this period, they do not normalize or significantly decrease after 5 years post-menopause. - The hormonal changes of menopause are permanent, not transient. *Incorrect: 10 years* - Similar to the 5-year period, gonadotropin levels remain elevated and do not revert to pre-menopausal levels after 10 years. - The physiological shift is permanent. *Incorrect: 2 years* - The initial years immediately following menopause (**perimenopause** and early post-menopause) are marked by significantly elevated gonadotropin levels. - However, these levels remain high indefinitely, indicating a permanent physiological shift, not a temporary elevation that resolves after only 2 years.

Q: Which of the following is a beneficial effect of hormone replacement therapy in early menopause?

Increased Nitric oxide. ***Increased Nitric oxide*** - **Estrogen** in HRT increases the production and bioavailability of **nitric oxide (NO)** by upregulating endothelial nitric oxide synthase (eNOS). - Increased NO leads to **vasodilation**, contributing to cardiovascular benefits and improved endothelial function. *Increased Endothelin* - **Endothelin-1** is a potent vasoconstrictor, and increased levels are generally associated with **endothelial dysfunction** and cardiovascular risk. - HRT, particularly estrogen, tends to decrease endothelin-1 levels or counteract its effects, leading to beneficial vascular responses. *Increased TNF-α* - **Tumor Necrosis Factor-alpha (TNF-α)** is a pro-inflammatory cytokine, and elevated levels are linked to chronic inflammation and increased risk of various diseases. - HRT, especially estrogen, typically has **anti-inflammatory effects**, potentially reducing TNF-α levels or mitigating its inflammatory actions. *Decreased COX-2* - **Cyclooxygenase-2 (COX-2)** is an enzyme involved in inflammation and pain pathways; its decrease is generally anti-inflammatory. - However, the primary beneficial vascular effect of HRT is not through direct inhibition of COX-2 but rather through mechanisms like increasing nitric oxide.

Q: A 62-year-old woman presents for annual examination. Her last spontaneous menstrual period was 9 years ago, and she has been reluctant to use postmenopausal hormone replacement because of a strong family history of breast cancer. She now complains of diminished interest in sexual activity. Which of the following is the most likely cause of her complaint?

Decreased ovarian function. ***Decreased ovarian function*** - The woman's age and history of menopause 9 years prior strongly suggest **decreased ovarian function**, leading to **estrogen deficiency**. - **Estrogen deficiency** causes vaginal atrophy, dryness, and dyspareunia, which can significantly diminish interest in sexual activity. *Decreased vaginal length* - While vaginal atrophy can occur with menopause, leading to a narrower and less elastic vagina, a significant "decreased vaginal length" is less common as a primary cause of diminished sexual interest. - The primary physiological change affecting sexual interest due to estrogen loss is **vaginal dryness** and **dyspareunia**, rather than an anatomical change in length. *Untreatable sexual dysfunction* - Postmenopausal sexual dysfunction related to estrogen deficiency is often **treatable** with local vaginal estrogen therapy or other interventions. - Assuming it's untreatable without further assessment is premature and inaccurate, especially given the clear physiological changes associated with menopause. *Alienation from her partner* - While relationship issues can certainly affect sexual interest, the clinical history points to a **physiological cause** (postmenopausal estrogen deficiency). - There is no information in the scenario to suggest alienation from her partner, making this answer less likely than a direct physiological cause.

Q: Hormone Replacement Therapy (HRT) in postmenopausal women is beneficial in all these except

Prevention of CAD. ***Prevention of CAD*** - While HRT was initially thought to be cardioprotective, large-scale studies like the **Women's Health Initiative (WHI)** demonstrated that it does **not prevent coronary artery disease (CAD)** and may even increase the risk of cardiovascular events, especially in older postmenopausal women or those initiating therapy years after menopause. - The potential benefits regarding CAD prevention are outweighed by risks such as **stroke** and **venous thromboembolism**. *Vaginal atrophy* - **Estrogen deficiency** in postmenopausal women leads to thinning, dryness, and inflammation of the vaginal walls, causing symptoms like dryness, irritation, and painful intercourse. - **Local or systemic estrogen therapy** effectively reverses these changes by restoring vaginal tissue health. *Osteoporosis* - **Bone loss** accelerates after menopause due to declining estrogen levels, increasing the risk of osteoporosis and fractures. - HRT, particularly estrogen, is effective in **preventing and treating osteoporosis** by inhibiting bone resorption and preserving bone mineral density. *Vasomotor symptoms* - **Hot flashes** and **night sweats** are common and often debilitating symptoms of menopause, directly linked to fluctuating and declining estrogen levels. - HRT, especially systemic estrogen, is the **most effective treatment** for alleviating these symptoms by stabilizing thermoregulatory control.

Question 1

A 50 year old postmenopausal woman comes with complaints of bleeding per vaginum. Which one of the following investigations is NOT required?

Accepted Answer

Diagnostic laparoscopy

Answer

Hysteroscopy

Answer

Pap smear

Answer

Endometrial biopsy

Question 2

Which of the undermentioned conditions does not cause postmenopausal vaginal bleeding?

Accepted Answer

Benign cystic teratoma of ovary

Answer

Carcinoma of cervix

Answer

Senile vaginitis

Answer

Prolapse of uterus with decubitus ulcer

Question 3

Menopause is associated with the following except:

Accepted Answer

Delusion

Answer

Loss of libido

Answer

Ischemic heart disease

Answer

Osteoporosis

Question 4

A 58 year old woman, post menopausal for last 8 years comes with history of spotting per vaginum. What is the most likely cause?

Accepted Answer

Atrophic vaginitis

Answer

Endometrial hyperplasia

Answer

Endometrial carcinoma

Answer

Estrogen replacement therapy

Question 5

Which of the following is an established benefit of Hormone Replacement Therapy (HRT)?

Accepted Answer

Decreased risk of vertebral fracture

Answer

Decreased risk of endometrial cancer

Answer

Decreased risk of breast cancer

Answer

Decreased risk of colon cancer

Question 6

Treatment of post menopausal osteoporosis are all EXCEPT

Accepted Answer

Magnesium and Zinc

Answer

Estrogen

Answer

Calcium, Vit D supplementation

Answer

Raloxifene

Question 7

Gonadotrophins remain elevated after menopause for :

Accepted Answer

Rest of life

Answer

5 years

Answer

10 years

Answer

2 years

Question 8

Which of the following is a beneficial effect of hormone replacement therapy in early menopause?

Accepted Answer

Increased Nitric oxide

Answer

Increased Endothelin

Answer

Increased TNF-α

Answer

Decreased COX-2

Question 9

A 62-year-old woman presents for annual examination. Her last spontaneous menstrual period was 9 years ago, and she has been reluctant to use postmenopausal hormone replacement because of a strong family history of breast cancer. She now complains of diminished interest in sexual activity. Which of the following is the most likely cause of her complaint?

Accepted Answer

Decreased ovarian function

Answer

Decreased vaginal length

Answer

Untreatable sexual dysfunction

Answer

Alienation from her partner

Question 10

Hormone Replacement Therapy (HRT) in postmenopausal women is beneficial in all these except

Accepted Answer

Prevention of CAD

Answer

Vaginal atrophy

Answer

Osteoporosis

Answer

Vasomotor symptoms

Menopause — MCQs

Menopause — MCQs

On this page

Practice by Chapter

Want unlimited practice?